Evolution of the Average Target: AstraZeneca PLC

Evolution of the Average Target - AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Evolution of the Target Price - AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

9e790814228928bcb09da4ba8.2GuIO20N8E77rryL-j2XsrI1WYh7P4y_ANANWYwlu-Q.kxrSbwNBvBG6xMTdnXzw5tViAOw-Us7lZedcGPVJiKPqEcR6PDS0drji_Q~fceac42d00d9ae167a3f9148b66bf0d2
16/10 AstraZeneca PLC : Berenberg remains its Buy rating ZD
16/10 RBC Reaffirms AstraZeneca's Outperform Rating Ahead of Q3 Results MT
15/10 AstraZeneca PLC : UBS gives a Buy rating ZD
15/10 AstraZeneca PLC : Gets a Buy rating from RBC ZD
14/10 AstraZeneca PLC : Deutsche Bank reiterates its Neutral rating ZD
07/10 Berenberg Trims AstraZeneca PT, Affirms Outperform Rating MT
07/10 Deutsche Bank ups Glencore, BHP price targets AN
07/10 AstraZeneca PLC : Buy rating from Berenberg ZD
07/10 AstraZeneca PLC : Jefferies gives a Buy rating ZD
07/10 AstraZeneca PLC : Bernstein reaffirms its Buy rating ZD
06/10 Genmab in Good Health, Schneider Lacks Energy Zonebourse
06/10 BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum MT
30/09 AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating ZD
30/09 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
29/09 Stocks Defy the Pressure Zonebourse
29/09 AstraZeneca PLC : Jefferies keeps its Buy rating ZD
29/09 AstraZeneca PLC : RBC reaffirms its Buy rating ZD
29/09 AstraZeneca PLC : JP Morgan maintains a Buy rating ZD
29/09 AstraZeneca PLC : Deutsche Bank is Neutral ZD
18/09 Berenberg and Deutsche say buy Bytes Technology AN
16/09 AstraZeneca PLC : Gets a Buy rating from UBS ZD
16/09 Oddo BHF cuts Safestore to neutral, cuts target AN
16/09 AstraZeneca PLC : Buy rating from Jefferies ZD
16/09 AstraZeneca PLC : JP Morgan keeps its Buy rating ZD
16/09 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+24.17%
+6.11%
+10.32%
-0.28%
+9.26%
-0.65%
-1.09%
-9%
+1.57%
+15.37%
Average +5.58%
Weighted average by Cap. +5.59%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
166.04USD
Average target price
210.50USD
Spread / Average Target
+26.78%
High Price Target
262.96USD
Spread / Highest target
+58.38%
Low Price Target
154.83USD
Spread / Lowest Target
-6.75%

Analyst Consensus Detail

Analyst consensus - AstraZeneca PLC

Consensus revision (last 18 months)

Consensus revision (last 18 months) - AstraZeneca PLC
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - AstraZeneca PLC
  1. Stock Market
  2. Stocks
  3. AZN Stock
  4. Consensus AstraZeneca PLC